

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 4, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3218 Filed 2-18-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Quantitative Imaging for Evaluation of Responses to Cancer Therapies.

Date: March 4, 2010.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Viatcheslav A Soldatenkov, M.D., PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8057, Bethesda, MD 20892-8329. 301-451-4758. soldatenkov@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, SBIR Topic 258.

Date: March 25, 2010.

Time: 12:30 p.m. to 5:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6116 Executive Boulevard, Room 210, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Viatcheslav A Soldatenkov, M.D., PhD, Scientific Review Officer, Special Review and Logistics Branch,

Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8057, Bethesda, MD 20892-8329. 301-451-4758. soldatenkov@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, SBIR Topic 276.

Date: March 26, 2010.

Time: 12:30 p.m. to 5:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6116 Executive Boulevard, Room 210, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Viatcheslav A Soldatenkov, M.D., PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8057, Bethesda, MD 20892-8329. 301-451-4758. soldatenkov@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Portable e-Technology Diet and Physical Activity Tools for Consumers.

Date: April 7, 2010.

Time: 11 a.m. to 3 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6116 Executive Boulevard, Room 405, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Marvin L. Salin, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892-8329. 301-496-0694. msalin@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 4, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3189 Filed 2-18-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; The Early Detection Research Network: Clinical Validation Centers.

Date: March 17, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Legacy Hotel and Meeting Center, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Lalita D. Palekar, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7141, Bethesda, MD 20892, 301-496-7575, palekarl@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Cancer Nanotechnology Training (R25) and Career Development Award (K99/R00) Applications.

Date: March 23-24, 2010.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Jeannette F Korczak, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8115, Bethesda, MD 20892, 301-496-9767, korczakj@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 4, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3191 Filed 2-18-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and

Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 74 FR 68630–3 1, dated December 28, 2009) is amended to reflect the establishment of the Office of Noncommunicable Diseases, Injury and Environmental Health.

Section C–B, Organization and Functions, is hereby amended as follows:

After the mission statement for the Centers for Disease Control and Prevention (C), delete the title and insert the following:

Office of Noncommunicable Diseases, Injury and Environmental Health (CU). The mission of the Office of Noncommunicable Diseases, Injury and Environmental Health (ONDIEH) is to reduce the burden of noncommunicable diseases, injuries, disabilities and environmental health hazards.

Office of the Director (CUA). (1) Advises the CDC Director on issues related to noncommunicable diseases, injury prevention, disability, and environmental health; (2) provides overall strategic direction and leadership for noncommunicable diseases, injury prevention, disability and environmental health; (3) promotes and supports noncommunicable diseases, injury prevention, disability, and environmental health related science, policies and programs; and (4) identifies, facilitates, and promotes cross center and cross-agency collaboration, innovation, and new initiatives related to noncommunicable diseases, injury prevention, disability, and environmental health.

Dated: February 3, 2010.

William P. Nichols,

Acting Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2010–3069 Filed 2–18–10; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0376]

Office of the Commissioner Reorganization; Statement of Organizations, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the

reorganization of the Office of the Commissioner (OC). This reorganization includes the organizations and their substructure components as listed in this document. This notice was previously published in the **Federal Register** of August 18, 2009, but it contained several errors. For the convenience of the reader, the reorganization is being published again in its entirety.

FOR FURTHER INFORMATION CONTACT:

Vanessa Starks, Office of Management Programs (HFA–400), Food and Drug Administration, 5600 Fishers Lane, rm. 6B–42, Rockville, MD 20857, 301–827–1463.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 18, 2009 (74 FR 41713), FDA published a notice announcing the reorganization of the Office of the Commissioner (OC). This reorganization includes the realignment of four Deputy-level offices within OC. They are as follows: (1) The Office of the Chief Scientist; (2) the Office of Administration (formerly titled the Office of Operations); (3) the Office of Foods; and (4) the Office of Policy, Planning and Budget (formerly titled the Office of Policy, Planning and Preparedness).

Office of Chief of Staff: The Office of Chief of Staff will advise and provide integrated policy analysis and strategic consultation to the Commissioner, the Principal Deputy Commissioner, Deputy Commissioners, and other senior FDA officials on activities and issues that affect significant agency programs, projects and initiatives. Often this function involves the most difficult problems, crisis situations and extremely complex issues of the Agency. This Office will include the Executive Secretariat Staff. This Office will report directly to the Commissioner.

Office of Legislation: The Office of Legislation will be restructured from the Office of the Chief of Staff. The Office of Legislation will report directly to the Commissioner and have an indirect reporting relationship to the Deputy Commissioner for Policy, Planning and Budget.

Office of Policy, Planning and Budget: The Office of Policy, Planning and Budget will be retitled from the Office of Policy, Planning and Preparedness. The Office of Policy, Planning and Budget will be restructured to consist of the Office of Policy, the Office of Planning and the Office of Budget (formerly the Office of Budget Formulation and Presentation). The Office of Policy will consist of the Policy Development and Coordination

Staff, Regulations Policy and Management Staff, and Regulations Editorial Section. The Office of Planning will consist of the Planning Staff, Evaluation Staff, Economic Staff, Risk Communication Staff, and Business Process Planning Staff. The Office of Policy, Planning and Budget will report directly to the Commissioner.

Office of the Counselor to the

Commissioner: The Office of the Counselor to the Commissioner will be established to formulate and render advice to the Commissioner that is related to policy development, interpretation, and integration that cuts across program lines or which is not well defined. This Office will include the Office of Crisis Management. The Office of the Counselor to the Commissioner will report directly to the Commissioner.

Office of Women's Health: The Office of Women's Health will be realigned from the Office of the Chief Scientist, Office of Science and Health Coordination. The Office of Women's Health will report directly to the Commissioner.

Office of Special Medical Programs:

The Office of Special Medical Programs is a newly created Office within OC with functions and substructure realigned from components of existing offices. The Office of Special Medical Programs will consist of the following components: Office of Pediatric Therapeutics, Office of Combination Products, Office of Orphan Product Development, and Office of Good Clinical Practice (formerly titled the Good Clinical Practice Program) which all will be realigned from the Office of the Chief Scientist. The Office of Special Medical Programs will also include the Advisory Committee Management and Oversight Staff (formerly in the Office of Policy, Planning, and Preparedness). This Office will report directly to the Commissioner.

Office of External Affairs: The Office of External Affairs will be established to serve as a focal point for improving FDA's communications to media, Congress, and the general public; and to also advise the Commissioner on better internal communications within the Agency. This Office will consist of the Office of External Relations, the Office of Public Affairs and the Office of Special Health Issues. This Office will report directly to the Commissioner.

Office of Foods: The Office of Foods will be established to elevate and empower our food safety activities. This office, led by the Deputy Commissioner for Foods, will provide executive leadership and management to all FDA food programs, and will be accountable